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A B S T R A C T   
Background: Cardiovascular disease (CVD) accounts for 40% of the excess mortality identified in people with 
severe mental illness (SMI). Modifiable CVD risk factors are higher and can be exacerbated by the cardiome-
tabolic impact of psychotropic medications. People with SMI frequently attend primary care presenting a va-
luable opportunity for early identification, prevention and management of cardiovascular health. The ACCT 
Healthy Hearts Study will test a coproduced, nurse-led intervention delivered with general practitioners to re-
duce absolute CVD risk (ACVDR) at 12 months compared with an active control group. 
Methods/design: ACCT is a two group (intervention/active control) individually randomised (1:1) controlled trial 
(RCT). Assessments will be completed baseline (pre-randomisation), 6 months, and 12 months. The primary 
outcome is 5-year ACVDR measured at 12 months. Secondary outcomes include 6-month ACVDR; and blood 
pressure, lipids, HbA1c, BMI, quality of life, physical activity, motivation to change health behaviour, medi-
cation adherence, alcohol use and hospitalisation at 6 and 12 months. Linear mixed-effects regression will 
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T
estimate mean difference between groups for primary and secondary continuous outcomes. Economic cost- 
consequences analysis will be conducted using quality of life and health resource use information and routinely 
collected government health service use and medication data. A parallel process evaluation will investigate 
implementation of the intervention, uptake and outcomes. 
Discussion: ACCT will deliver a coproduced and person-centred, guideline level cardiovascular primary care 
intervention to a high need population with SMI. If successful, the intervention could lead to the reduction of the 
mortality gap and increase opportunities for meaningful social and economic participation. 
Trial registration 
ANZCTR Trial number: ACTRN12619001112156.   
1. Introduction 
1.1. Background and rationale 
People with severe mental illnesses (SMI) such as psychosis, schi-
zophreniform disorders, bipolar disorder and major depression are at 
increased risk of cardiovascular disease (CVD) and metabolic syndrome 
than those without SMI. [1,2] Antipsychotic use can dramatically in-
crease CVD risk in people with SMI [3,4], but modifiable risk factors 
contribute substantially and include abdominal obesity, insulin re-
sistance/glucose intolerance, high blood pressure, high cholesterol, 
physical inactivity, diet, smoking, and alcohol or other drug use. [5–8] 
This is further complicated by systemic issues of poor care integration 
across health and social care sectors and stigma. 
Although CVD-related mortality rates have declined in the general 
population, [9,10] CVD continues to contribute 40–50% [11] of the 
10–25 year mortality gap for people with SMI. [12] The Australian 
Survey of High Impact Psychosis (SHIP) reported cardiometabolic ill-
ness rates that were substantially higher in people with SMI compared 
with the general population for diabetes (21% vs 4.9%); heart or cir-
culatory conditions (27% vs 4.8%) and high cholesterol (31% vs 6.1%). 
[13,14] Medication was being taken by 52% diagnosed with hy-
pertension; 40% diagnosed with diabetes/hyperglycaemia; and 40% 
diagnosed with high cholesterol. [5] High 5-year absolute cardiovas-
cular disease risk (ACVDR) was identified in 24% of SMI respondents, 
and 7% had moderate risk [5] compared against the general population 
where 11.9% had high and 8.8% had moderate risk. [15] ACVDR is 
determined through the use of algorithms that determine a person's risk 
of developing CVD or having a cardiac event based on key risk factors. 
Internationally, the Framingham Risk Equation [16] is most widely 
used, and the Australian version is based on this tool [17]. Importantly, 
general population ACVDR algorithms may underestimate risk for 
people living with SMI by up to two thirds. [18] 
The increased CVD risk for people with SMI compared with people 
without SMI indicates that people with SMI should be viewed as a high- 
risk population for CVD. Currently, Australian medical guidelines do 
not address this elevated risk, outside advice for smoking cessation. 
(e.g. [19]) It is recognised that the integration of evidence-based life-
style interventions for physical health in mental healthcare is an es-
sential first step to addressing the life expectancy gap. [20] 
Reduction of ACVDR is difficult to achieve in all populations, and 
successful interventions in people with SMI have often achieved only 
small to medium effects. [21] Larger effects have been reported when 
interventions were multifactorial, tailored, enduring, targeted at people 
with elevated risk, and combined pharmacological and non-pharma-
cological approaches. [21–25] Clinical impacts were maximised when 
people with SMI were engaged for sufficient duration and contact. [25] 
Increasingly this success is linked with people with lived-experience 
coproducing interventions that incorporate their expertise and views. 
[26,27] Given that people with SMI have been documented to attend 
general practice twice as frequently than the general population (9 vs 5 
times annually), [13] primary care presents an important setting for the 
delivery of interventions to reduce ACVDR for people with SMI. This 
builds on the central role primary care has in the prevention, detection, 
monitoring and treatment of ACVDR. [28] 
We outline the protocol for a stratified, individually randomised 
controlled trial (RCT) of a 12-month coproduced assertive cardiac care 
intervention for individuals with SMI attending general practice; ACCT. 
The protocol follows the SPIRIT guidelines for RCTs. [29] 
2. Materials and methods 
2.1. Objectives 
2.1.1. Primary objective 
To determine whether the ACCT intervention, a nurse-led colla-
boration with GPs to deliver multifactorial CVD risk reduction in-
corporating tailored pharmacological and non-pharmacological ap-
proaches, reduces the 5-year absolute cardiovascular disease risk 
(ACVDR) in people with SMI at 12 months relative to an active control 
group. 
2.1.2. Secondary objectives 
To determine whether the ACCT intervention will differ from an 
active control in improving 6-month ACVDR; and systolic and diastolic 
blood pressure, total cholesterol, HDL and LDL cholesterol, triglycer-
ides, HbA1c (12 months only), BMI; quality of life, physical activity, 
motivation to change health behaviour, medication adherence, alcohol 
use and hospitalisation compared to active controls at 6 months and 
12 months. An economic cost-consequences analysis of health economic 
factors and a parallel process evaluation will be conducted. Outcome 
measures are further described below. 
2.2. Trial design 
The ACCT study is a 2 group (intervention/active control) in-
dividually randomised RCT with assessments at baseline, 6 months and 
12 months post-randomisation. 
2.3. Methods: participants, interventions, and outcomes 
2.3.1. Study setting 
This study will be conducted in primary care which includes general 
practices and community health centres across Victoria, Australia. 
There are over 1600 accredited general practices across Victoria [30] 
and 86 Community Health Services made up of 31 independently 
managed community health centres and 55 services that are a part of 
larger rural or metropolitan health services. Urban, rural and regional 
sites will be recruited that are responsible for the delivery of clinical 
and/or psychosocial recovery services. As patient diagnostic, clinical 
and contact data is held in clinic-specific electronic medical record 
software, individual sites will be recruited followed by an invitation to 
individuals [31]. 
2.3.2. Eligibility criteria 
Primary care sites (general practices and community health centres) 
will be eligible to be enrolled in the study if they: 
M. Lewis, et al.   Contemporary Clinical Trials 97 (2020) 106143
2
- provide care for people who meet study inclusion criteria (Table 1);  
- can assist to identify and contact eligible patients;  
- have general practitioners (GPs) willing to be involved and retain 
clinical responsibility for their patients;  
- can provide, subject to individuals granting consent, access to each 
participant's practice medical records; and  
- have a space (where required) available for the researchers to meet 
with study participants. 
Patients will be eligible if they meet the inclusion and exclusion 
criteria listed in Table 1. 
The age limits ensure that the sample will meet the age restrictions 
for the ACVDR calculation. The ACVDR age range is 45–74 years but 
guidelines allow for the inclusion of some populations with elevated 
risk aged from 35 years (such as Aboriginal and Torres Strait Islanders). 
This age criterion has been extended to the SMI population in this 
study. [17] Women who are pregnant or breastfeeding will be excluded 
due to potential for impact on the cardiometabolic endpoints and dis-
tortion of outcome data. People who are experiencing an acute manic or 
psychotic episode will be ineligible at that time but can be approached 
again after two weeks to one month to provide a flexible participation 
option. This accords with clinical advice that acute symptoms could 
resolve within two weeks following active treatment. 
Eligible participants will be invited to complete a Healthy Heart 
Check with a research nurse using point of care (POC) testing at their 
usual practice to determine ACVDR. [17] Everyone who attends a 
Healthy Heart Check will be provided with a coproduced ACCT Healthy 
Hearts Information booklet that contains general information on ways 
to maintain or improve cardiovascular health based on established 
guidelines. 
People who have an ACVDR ≥3% will be eligible to be randomised 
to intervention or active control. Participants who score  <  3% ACVDR 
will not meet study eligibility criteria and will be informed of a lower 
risk result. They will be offered the opportunity to join the Co-Design 
Living Labs—a research registry of people with lived experience who 
take part in co-design, intervention development, piloting and proto-
type development and research translation. The 3% ACVDR minimum 
has been adopted to ensure that participants have some level of risk that 
can be addressed in the study, and to minimise the chance that floor 
effects could be observed in the primary outcome variable. 
2.3.3. Interventions 
Participants that meet the eligibility criteria will be randomised to 
the Assertive Cardiac Care Intervention Group or Active Control group. 
2.3.3.1. Assertive cardiac care intervention group 
2.3.3.1.1. Intervention overview. The Assertive Cardiac Care 
intervention has been coproduced by people who have lived 
experience of SMI, a multidisciplinary team of clinicians and mental 
health researchers. Box 1 describes the coproduction process 
undertaken to develop the intervention (see Box 1). In brief, the 
Assertive Cardiac Care intervention integrates guideline level CVD 
preventive care with key principles of Assertive Community 
Treatment (ACT: [32]) and Motivational Interviewing (MI). [33] An 
integrated, person-centred approach has been employed based on 
Assertive Community Treatment principles including assertive 
outreach, a coordinated team approach, frequent contact in the 
community, a focus on self-determination and active medication 
management. [32,34] This is supplemented by a MI-informed 
approach where the motivation to change is elicited from a person 
through engagement and understanding of the person's readiness to 
change. MI is a collaborative process that is ongoing and supportive to 
elicit and maintain the motivation for change, as well as supporting the 
development of confidence, strategies and the resilience to overcome 
potential barriers to change [35,36]. The intervention will be delivered 
over 12 months. 
A training program for research nurses has been developed by in-
vestigators in the team with input from GPs, nurses, psychiatrists 
(trained in ACT) and a clinical psychologist (trained in MI). Training 
will be delivered by those team members with support from the trial 
manager and refresher training is planned during the intervention 
course. Research nurses will be trained in completion of ACVDR as-
sessments (Healthy Heart Checks) using POC testing (explained below) 
and the use of the purposefully built digital platform that has a dual 
function of being the study database and houses the intervention 
components (conversation aid, goals form and actions, healthy heart 
action plan, phone and SMS tailored message and short form risk re-
duction guidance for nurses). This is followed by comprehensive 
training in the intervention which includes dedicated skills develop-
ment for MI and ACT and coproduced intervention components. 
Training will be conducted over two, three-hour sessions. Research 
nurses will receive ongoing support from study investigators. Fig. 1 
describes the conceptual theoretical model and the active ingredients of 
the assertive cardiac care intervention. 
An additional program has been developed for study research as-
sistants for data collection using the digital study platform. Research 
assistants will not be involved in intervention delivery. 
Following completion of ACVDR, the intervention has two key 
components:  
- The Healthy Hearts Action Plan Appointment  
- Provision of Assertive Support 
2.3.4. The healthy hearts action plan appointment 
At the completion of the Healthy Heart Check participants who are 
randomised to the Intervention Group will be booked to attend a 
Healthy Hearts Action Plan appointment. This appointment may take 
up to 60 min and the participants and the research nurse will:  
- discuss the ACVDR results and risk factors that contribute to CVD 
risk;  
- discuss CVD risks that the participant may experience using the co- 
Table 1 
Participant Inclusion and Exclusion Criteria for ACCT.    
Participants 
Inclusion criteria Exclusion criteria   
- age 35–74 years reflecting the parameters of the ACVDR calculation algorithm  
- ability to understand instructions of the study in English and complete questionnaires without an 
interpreter  
- existing diagnosis of schizophrenia, bipolar disorder, major depression, or recording of psychosis, or 
other SMI identified  
- OR currently prescribed anti-psychotic medication  
- severe acute manic or psychotic episode (unresolved)  
- acute physical illness or existing cardiac condition  
- previous CVD event  
- unable to provide informed consent at time of enrolment  
- pregnancy or breastfeeding 
+   
- ACVDR ≥3% (determined at the Baseline Healthy Heart Check)  
- ACVDR  < 3% (determined at the Baseline Healthy Heart 
Check) 
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produced conversation aid;  
- develop goals and actions to reduce ACVDR; and  
- complete a management plan for ACVDR in conjunction with the 
participant's GP. 
The digital study platform calculates the ACVDR based on data 
collected in the Healthy Heart Check and generates a “risk arrow” 
outlining the person's ACVDR. The “risk arrow” is based on the format 
used by the National Vascular Disease Prevention Alliance in ACVDR 
management guidelines [37] to indicate the broad level of identified 
risk (see Fig. 2). Feedback from the coproduction cycles indicated the 
arrow format was easy to interpret and was user-friendly for people 
with lived-experience of SMI. The research nurse and the participant 
will use the “risk arrow” to enter into the discussion about ACVDR and 
the factors that contribute to this risk. 
In presenting the risk results, research nurses will adopt a MI ap-
proach which attempts to identify the person's existing knowledge and 
motivation they might already have about their CVD risk and to build 
on this to facilitate change. Responses will guide the discussion between 
the participant and research nurse about how the relevant CVD risks 
could be addressed with pharmacological (where indicated) and non- 
pharmacological treatments. Nine areas for improvement for heart 
health are outlined using the coproduced conversation aid. These im-
provement areas are documented in current guidelines as ways to im-
prove heart health and include making changes to salt consumption, 
drinking alcohol, eating healthy food, smoking, exercise, strength 
building, alcohol use, take away foods, inactivity and loneliness/stress 
where indicated and possible. The conversation aid has been designed 
with guiding questions and responses modelled on MI to foster parti-
cipants' own reasons for making changes and to address key CVD risk 
Box 1 
Coproduction cycles for the assertive cardiac care intervention 
Six iterative coproduction cycles were held with people with lived-experience of SMI to determine how to (a) present heart health information, 
(b) develop tools to support risk conversations and decision-making, (c) encourage uptake of interventions to reduce CVD risk, and (d) co- 
design an intervention fit for purpose. 
The first coproduction cycle involved ten people with lived-experience of SMI. In this group people discussed the content, format and 
wording of publicly available heart health information or cardiovascular risk information from the internet which represented guidance from 
the UK, US and Australia. Participants identified what worked and what did not work in the guidance provided, including seletion of preferred 
images to communicate information. 
The first coproduction cycle identified three key intervention components: 1) the need for a conversation aid to support CVD risk discussion 
and the identification of areas for change, 2) the need for a take home option for actions that was simple, easy to read and store at home but 
visually engaging, and 3) a healthy heart information booklet. 
Prototypes of possible conversation aids were formulated and tested out in three more coproduction cycles conducted with a new group of 
participants who also had experience of living with SMI. A graphic designer was engaged to develop graphics to represent nine CVD risk factors 
and a final conversation aid prototype was produced based on lived experience participant preferences. A healthy hearts information booklet 
and a take home action form were also developed to support the intervention delivery. The information booklet used the same graphics as the 
conversation aid to ensure consistency in approach and messaging, and combined evidence from existing CVD guidelines about risk reduction 
in a format that was understandable and straightforward. 
The final materials were shared with participants in a fifth coproduction cycle. These were deemed to be acceptable and feasible to that 
group. As part of the coproduction cycle we also consulted with five multidisciplinary professionals to gather feedback on the conversation aid 
and information booklet. There were minimal changes that followed these sessions. The sixth coproduction cycle included a pilot of the 
intervention with people with lived-experience to ensure fit for purpose.  
Fig. 1. The conceptual theoretical model and active ingredients of the assertive cardiac care intervention.  
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factors. The responses to the conversation aid will indicate which areas 
an individual seeks to improve. These responses will be used to inform 
goals for change and can be re-visited in future intervention contacts. 
The conversation aid is completed collaboratively via a digital platform 
or as a paper-based tool depending on participant preference. If the 
paper-based aid is used, the answers will be entered into the digital 
platform to maintain the study record. 
Up to two behavioural/lifestyle targets for change to reduce ACVDR 
will be collaboratively decided on by the participant and nurse, in-
cluding identification of risk factors that warrant pharmacological 
treatments. Participants will then use the targets to work with the re-
search nurse to develop actions to support goals that are meaningful 
and reflect the participant's confidence, motivation and circumstances. 
A SMART (Specific; Measurable; Achievable; Relevant; Time-Bound) 
format will guide goal and action formulation. [38] The selected goals 
will be recorded alongside the actions in the digital platform, and 
participants will be provided a hard copy version of these goals and 
actions to take home. 
The final step in the Healthy Hearts Action Plan appointment will be 
to document the goals and actions with input from the participant's GP. 
The GP will collaborate in a review of the Healthy Heart Check results 
and discuss the plan developed to reduce ACVDR for the participant. 
The GP will initiate medication as indicated based on ACVDR level and 
their clinical judgement. Treatment recommendations will be based on 
national guidelines [19,39] and have been developed into short form 
guidance accessible within the digital platform for the GP and research 
nurse. The GP and research nurse will document the Healthy Hearts 
Action Plan with the participant using a template within the digital 
platform. Key components of the Healthy Hearts Action Plan will be 
prefilled within the digital platform drawn from the baseline ques-
tionnaires and Healthy Heart Check. The Healthy Hearts Action Plan 
incorporates the main components of a GP management plan and/or 
chronic disease management plan and conforms with routine structures 
and payment systems for Australian general practice. 
2.3.5. Assertive support 
Following the Healthy Hearts Action Plan, intervention participants 
will receive assertive support from the research nurse additional to 
usual care provided by the GP. All ongoing contacts will be scheduled 
and structured within the digital platform with data entered as it is 
being collected. The research nurse delivering the intervention will 
provide:  
- Weekly phone contact that alternates each week between phone 
calls and positive messages via SMS. The contacts will be conducted 
using MI techniques and use a semi-structured approach allowing 
the participant to guide the discussion, update progress and trou-
bleshoot barriers. At each fortnightly phone call the research nurse 
will be able to access and refer to the person's goals in the digital 
platform. Research nurses will work with the person to understand 
progress toward the goals and what has been working well, and any 
impediments to progress. The goals can be modified using the 
SMART Goal format if they have been attained; if they are judged 
too difficult; if they are demotivating the person; or as the person's 
health or life circumstances change. Any updates to established 
goals will be tracked and the reasons for the changes recorded in the 
digital platform. 
- The SMS messaging in alternate weeks will be tailored to the in-
dividual to foster activation to achieve the set goals through sup-
portive feedback, encouragement and motivation. The messages aim 
to reflect the participant's actions and goals, and will be guided by 
example messages that will be provided in the nurse manual. 
Messages will be collated within the participant record in the digital 
platform. 
- In-person appointments with a research nurse: Intervention parti-
cipants will meet with the research nurse at week 6, 12, 26, 38 and 
52. These will coincide with Healthy Heart Checks and assessments 
at 26 weeks and 52 weeks. Some participants may not need to attend 
6, 12 and 38 week appointments if they have not had medication 
initiated by the GP in the study.  
- The GPs of intervention participants will be provided a summary of 
the Healthy Heart Check from the baseline, 6-month and 12-month 
assessments. GPs will collaborate in the in-person appointments to 
discuss the Healthy Hearts Action Plan, review medications, initiate 
and monitor referrals and monitor progress. Ongoing usual care will 
be maintained between times. GP study involvement will be re-
corded in the digital platform.  
- At 52 weeks the research nurse will complete a handover process 
with the GP and participant. Goal progression over the year will be 
reviewed alongside all Healthy Heart Check results. Efforts to en-
gage and motivate the participant will be made and strategies to 
maintain motivation and momentum to achieve the goals will be co- 
Fig. 2. Mock example of Absolute Cardiovascular Disease Risk Communication Arrow [37].  
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developed. A printed study summary will be presented to the GP and 
participant. 
2.3.5.1. ACCT active control group. Participants allocated to active 
control group will receive the coproduced Healthy Hearts Information 
booklet, and a recommendation to book an appointment with a GP to 
follow up their cardiovascular health. Active Control participants will 
complete a Healthy Heart Check at baseline, 6 and 12 months but no 
results will be fed back to active control participants or their GP during 
the study. At 52 weeks the research nurse will complete a handover 
process where the GP and participant both receive a printed summary 
of all Healthy Heart Check results. 
Active controls will receive monthly calls from trained research 
assistants following a generic, scripted template designed to monitor 
any changes in health or treatment such as medication changes and any 
hospitalisation/s. These contacts will allow for other health issues to be 
brought to the attention of the research team. Information collected at 
these contacts will be recorded in the digital platform. Participants will 
be advised to direct any enquiries about their health to their GP. 
2.3.6. Outcomes 
Outcome assessments will be conducted prior to randomisation at 
baseline, and at 6 months and 12 months post-randomisation. 
Questionnaires will be administered by a research assistant via tele-
phone and Healthy Heart Checks conducted by a research nurse usually 
at the participants' primary care practice (or another setting where 
appropriate) to collect anthropomorphic measures. Study outcomes are 
listed in Table 2. 
2.3.6.1. Primary outcome. The primary outcome is change from 
baseline to 12 months post randomisation in 5-year ACVDR 
calculated using the algorithm developed by the National Vascular 
Disease Prevention Alliance (NVDPA). [17] ACVDR will be calculated 
at Healthy Heart Check appointments. These appointments will involve 
measures of blood pressure using an Omron HEM-907 (Omron 
Corporation; Vernon Hills, Illinois, USA) and Total Cholesterol and 
HDL cholesterol measured using the CardioChek PA (PTS Diagnostics; 
Whitestown, Indiana) POC blood pathology assessment device. POC 
cholesterol results will be used to determine the ACVDR at each Healthy 
Heart Check and will allow the ACVDR to be calculated within the 
Healthy Heart Check appointment. 
The CardioChek PA cholesterol results are subject to range restric-
tion (see Table 3). Contingencies have been developed to address this 
possibility. Results below the ranges shown in Table 3 will present a 
“LOW” reading on the POC device and results above the upper limits 
will show as “HIGH” on the POC device. If one of these results occurs, or 
an unexpected result occurs, a second test will be conducted with a new 
test strip. If on the second assessment the results remain outside the 
upper or lower limits, the following will occur: 
- if the POC reading value is LOW: The lower limit value should be 
included in the ACVDR calculation and updated with laboratory-based 
pathology results once they are available in the digital platform. 
- if the POC reading value is HIGH: The upper limit value of the POC 
device should be included in the ACVDR calculation and updated with 
laboratory-based pathology results once they are available in the digital 
platform. 
It is anticipated that these out of range values will be infrequent. In 
cases where this approach is required, the digital platform will include 
variables that indicate that the calculation is based on the laboratory- 
based pathology results and all subsequent ACVDR calculations will be 
based on the laboratory-based pathology results. 
2.3.6.2. Secondary outcome measures. Secondary outcome measures are 
outlined in Table 1 and are presented in more detail here. 
Table 2 
ACCT Study Outcome Measures and Assessment Timepoints.       
Timepoint 
Anthropomorphic measures (collected at 
Healthy Heart Check) 
Baseline 6 months 12 months  
5-year ACVDR risk score [17] X X X 
Systolic and diastolic blood pressure X X X 
Lipids (HDL cholesterol, LDL cholesterol, 
Triglycerides) 
X X X 
Glycated haemoglobin (HbA1c) X  X 
Body Mass Index (BMI) X X X       
Survey measures (collected via telephone interview) Baseline 6 months 12 months  
Assessment of Quality of Life 4D (AQOL-4D: [40]). X X X 
Motivation and Attitudes Toward Changing Health (MATCH: [41]) X X X 
International Physical Activity Questionnaire – Short Form (IPAQ: [42]) X X X 
Reported Adherence to Medication Scale (RAMS: [43]) X X X 
Alcohol Use Disorders Identification Test (AUDIT-C: [44]) X X X       
Hospitalisation data Baseline 6 months 12 months  
Emergency department presentations (Victorian Emergency Minimum Dataset) X X X 
Hospital admissions (Victorian Admitted Episodes Dataset) X X X       
Economic cost consequences analysis Baseline 6 months 12 months  
Health Resource Utilisation Questionnaire (HRUQ) X X X 
Medical Benefits Schedule Data X X X 
Pharmaceutical Benefit Schedule Data X X X 
Table 3 
CardioChek PA analyser range of measurement for Total Cholesterol and HDL 
Cholesterol.      
US units Australian units  
Total Cholesterol 100–400 mg/dl 2.59–10.36 mmol/l 
HDL cholesterol 15–100 mg/dl 0.39–2.59 mmol/l 
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2.3.6.2.1. 6 month ACVDR. The change in 5 year ACVDR [17] from 
baseline will be calculated at the 6 month Healthy Heart Check. 
2.3.6.2.2. Systolic and diastolic blood pressure. Measured in mm/hg. 
Blood pressure will be measured at baseline, 6 months and 12 months. 
Participants will be seated in a comfortable position and rested prior to 
the measurement of blood pressure. Three separate measurements will 
be recorded at least one to 2 min apart, and the second and third 
measures will be recorded in the database. 
2.3.6.2.3. Total cholesterol, High Density Lipoprotein (HDL) 
Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol and 
triglycerides. Non-fasting blood samples will be taken at baseline, 
6 months and 12 months. Total cholesterol and HDL cholesterol will 
Fig. 3. Participant timeline from initial contact, recruitment and flow through study.  
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be analysed using POC analysis solely for use in the ACVDR calculation. 
Additional blood samples taken at the Healthy Heart Checks will be 
analysed using standard pathology services available to each site and 
will be used as secondary outcome variables. LDL will be manually 
calculated. Results will be expressed as mmol/l. Existing pathology 
results in the primary care records for Tot-c, HDL-c, LDL-c and 
triglycerides within 6 months of the baseline assessment will be 
accepted as baseline measures to reduce the burden on participants. 
Clinicians within the investigator team determined that lipids collected 
within 6-months of baseline would be considered current. 
2.3.6.2.4. Glycated haemoglobin (HbA1c). Non-fasting blood 
samples will be taken at baseline and 12 months. HbA1c will be 
determined using standard pathology services available to each site. 
Results will be expressed as mmol/l. Existing pathology results in the 
primary care records for HbA1c within 6 months of the baseline 
assessment will be accepted as baseline measures to reduce the 
burden on participants. 
All GPs will have access to any laboratory pathology data that has 
been requested (Total, HDL & LDL cholesterol; Triglycerides; HbA1c) 
for all intervention and active control participants. 
2.3.6.2.5. Body mass index (BMI). Will be calculated in the digital 
portal at baseline, 6 months and 12 months. Height will be measured at 
the baseline assessment for all participants and weight will be measured 
at baseline, 6 months and 12 months. BMI is calculated using the 
formula: BMI = Weight (kg)/Height (m)2. Results will be expressed as 
kg/m2. 
2.3.6.2.6. Quality of life (QOL). The Assessment of Quality of Life 
4D (AQOL-4D: [40]) will be completed by participants at baseline, 
6 months and 12 months. It will be used both as a stand-alone measure 
of QOL and will be used in the health economic evaluation. Scoring will 
be conducted using standard approaches. The psychometric measure 
approach will be used to determine the stand-alone QOL score. The 
utility weight scoring system will be used in the health economic 
evaluation to estimate quality-adjusted life years (QALYs). 
2.3.6.2.7. Motivation and attitudes to change. The Motivation and 
Attitudes Toward Changing Health (MATCH: [41]) is an internally 
consistent and validated 9-item scale that provides a profile of factors 
influencing motivation that can be used in clinical and research 
settings. It assesses the domains of willingness, worthwhileness, and 
ability. Standard scoring will be used. Assessments will be conducted at 
baseline, 6 months and 12 months and data collected from MATCH will 
be utilised in the process evaluation to examine engagement and 
activation. 
2.3.6.2.8. Physical activity. The International Physical Activity 
Questionnaire – Short Form (IPAQ: [42]) measures the amount and 
type of physical activity conducted in the previous week. Standard 
scoring will be used. Assessments will be conducted at baseline, 
6 months and 12 months. 
2.3.6.2.9. Medication adherence. The Reported Adherence to 
Medication Scale (RAMS: [43]) is a 4-item scale to assess adherence 
to medication with specific focus on remembering to take medication, 
adjusting doses. RAMS has been used across a wide number of 
populations. RAMS will be completed at baseline, 6 months and 
12 months. Standard scoring will be used. 
2.3.6.2.10. Alcohol use. The Alcohol Use Disorders Identification 
Test (AUDIT-C: [44]) is a three item brief alcohol screen that identifies 
problematic levels of alcohol use and alcohol use disorders. Standard 
scoring will be used. 
2.3.6.2.11. Hospitalisation information (optional). Participants will 
be asked to provide consent for the researchers to request state held 
information on emergency department presentations via the Victorian 
Emergency Minimum Dataset (VEMD) and hospital admission data held 
in the Victorian Admitted Episodes Dataset (VAED). 
2.3.6.3. Economic outcomes. A comprehensive economic evaluation 
that draws data from several listed and supplementary outcome 
measures is embedded in the study. A cost-consequences analysis will 
compare the incremental costs of the intervention to the full spectrum 
of outcomes included in the study. Inclusion of the AQoL-4D enables a 
cost-utility analysis to be undertaken. The evaluation will measure: (1) 
any value change to the use of health care resources over the study 
period between the trial groups (including the costs of delivering the 
intervention to the intervention group) and (2) then compare any 
additional costs to the additional outcomes achieved using standardised 
“within trial” economic evaluation techniques. 
A study specific Health Resource Use Questionnaire (HRUQ) was 
modified from a resource use questionnaire frequently used in 
Australian mental health-related economic evaluations (e.g. [45]). The 
HRUQ covers service use and medication use, hospital use, accom-
modation, diagnostic tests, employment, National Disability Insurance 
Support (NDIS), and other services used. This will inform the economic 
evaluation along with the AQOL-4D [40]. The HRUQ covers a 6-month 
period and will be completed at baseline, 6 months and 12 months. 
Participants can provide optional informed consent for the research 
team to request federal government held Medicare Benefits Schedule 
(MBS) and Pharmaceutical Benefit Scheme (PBS) data that outline 
government reimbursed medical services and filled pharmacy pre-
scriptions. State government held data on hospital admissions and 
emergency department presentations will supplement the economic 
evaluation for the sample. 
2.3.7. Participant timeline 
Fig. 3 outlines the participant flow through the study for both the 
intervention and active control groups. Assessments at 6 and 12 months 
include a Healthy Heart Check conducted by a research nurse and 
questionnaires will be conducted over the telephone and administered 
by a research assistant. 
2.3.8. Sample size 
Randomisation of 504 individuals (252 per trial group) will provide 
80% power for a two-sided alpha level at 5% to detect a two-percentage 
point absolute difference in the mean 5-year risk for cardiovascular 
disease between the intervention and active control groups calculated 
using the Australian ACVDR Calculator at 12 months. [17] This be-
tween-group difference in means is consistent with previous studies 
using a similar care planning and coordination intervention and would 
constitute a clinically meaningful outcome. [7] Sample size estimation 
assumes a standard deviation of 6.7 [7] and allows for 30% loss to 
follow-up at 12 months based on the CORE study trial (which recruited 
participants with SMI from the community health setting) and other 
related studies conducted in this population. [46] 
2.3.9. Recruitment 
Recruitment will occur via two pathways. The first will be con-
ducted via General Practice clinics and Community Health Centres that 
have GPs within the service. The second recruitment pathway will be 
via psychosocial support services that do not have embedded GPs. 
2.3.9.1. General practice clinics and community health centres. General 
practices and Community Health Centres that meet the study inclusion 
criteria will be recruited into the study and sign an ACCT site 
agreement. Once a practice has enrolled into the study, practice 
administrative staff will work with a research team member to 
identify eligible patients. A list of patients that meet eligibility 
criteria (the patient list) will be developed for each practice. 
Eligible patients will be mailed an introductory letter to the study 
from the practice and university with a study brochure; study postcard 
and a reply-paid envelope. All patients on the “patient list” will be 
followed up by practice staff to ensure that the information was re-
ceived and to advise them about how to contact the research team to 
obtain further information or enrol in the trial. Additionally, the study 
brochure and study postcard will be left at participating sites allowing 
M. Lewis, et al.   Contemporary Clinical Trials 97 (2020) 106143
8
for opportunistic recruitment. Ethics requirements do not allow the 
research team to directly access identifiable information about the 
person until they contact the research team. 
People interested in taking part will contact the research team via a 
free-call number, study email address, or post their details. A researcher 
will address any queries that the potential participant has and will send 
a full plain language statement to the person via SMS, email or mail. A 
time will be made to contact the person and discuss the study further. 
People interested in participating in the trial will then commence en-
rolment and consent. 
2.3.9.2. Psychosocial support services. Community Health Centres that 
provide psychosocial support services to people with SMI will be 
approached as an avenue to invite eligible people. Staff working in 
these organisations will identify clients that meet the broad age and 
diagnostic criteria and present the information on the study. This will 
include a study postcard that people can complete and return to the 
research team, and a study email address and free-call number that can 
be used to contact the research team and express interest in 
participating. 
Once a person makes contact, the person will inform the research 
team of their GP and clinic. Contact will be made with the GP and clinic 
and the broad aims of the study will be discussed, and interest in the 
study gauged. If the GP and clinic agree to participate in the study, they 
will sign an ACCT Site Agreement, and can involve other patients in the 
practice if they are happy to do so. At this point the person will be 
informed and will complete the enrolment and consent process outlined 
below. 
If the GP and clinic are unable to participate in the study, the par-
ticipant will be informed that we will not be able to involve them in the 
study. The person will be offered the opportunity to be involved in 
other coproduced research through the department. 
2.3.9.3. Strategies for achieving adequate participant enrolment to reach 
target sample size. Both targeted and opportunistic recruitment 
strategies will be employed in the study. The avenues of recruitment 
include inviting potential participants via primary care clinics as well as 
via psychosocial support services delivered through community health 
centres. Site recruitment will continue until the target sample size has 
been reached. 
The recruitment approach will be actively monitored and assessed 
within the research team, the study Investigators and the Expert Data 
Monitoring Committee. Modifications to study recruitment will be 
submitted to ethics and updated on the trial registry. There is provision 
to extend the study into other states if required, and a decision to do 
this will be based on recruitment rates, resource availability and feed-
back from the Investigator group and the Expert Data Monitoring 
Committee. Participants will be provided with bi-annual study reports 
and primer materials sent for questionnaires and appointment re-
minders will utilise established engagement methods to encourage re-
tention. 
2.4. METHODS: assignment of interventions 
2.4.1. Allocation 
2.4.1.1. Sequence generation. Participants will be randomised in a 1:1 
ratio to the intervention or active control groups using a random 
allocation sequence generated using a biased-coin algorithm [47] and 
stratified by each primary care site. The imbalance tolerance of the 
randomisation algorithm is adaptive to ensure balance between trial 
group within the sites and overall. 
2.4.1.2. Allocation concealment mechanism and implementation. The 
randomisation algorithm is inbuilt into the digital study platform and 
will be activated after the Baseline questionnaire and Baseline Healthy 
Heart Check have been completed, and the participant meets all study 
inclusion criteria. Randomisation will use a biased-coin algorithm 
which allows group allocations to be concealed while maintaining 
equal allocation to both trial groups [48]. Research staff will have no 
knowledge or ability to influence group allocation. 
2.4.2. Blinding (masking) 
Consent and baseline assessment of participants will occur prior to 
randomisation to minimise selection and assessment bias. Due to the 
nature of the intervention we will use a single blind design where 
participants are blinded to their group allocation and are not informed 
whether they are allocated to the intervention or active control group. 
As the frequency and type of contact differs markedly between the in-
tervention and active control groups, research staff and GPs working 
directly with participants in the trial will be able to determine the group 
allocation of a participant by the tasks being completed. 
There is some risk of contamination between the trial groups, but it 
is anticipated that this will be small. GP clinics will be involved in the 
identification of potential participants, but the clinic and individual GPs 
will not be involved in the enrolment or consent of participants making 
it difficult for practice staff to know who is enrolled in the study and 
randomisation outcomes. The numbers of people with SMI are likely to 
be small per site given their low prevalence rate. As most of the in-
tervention and support delivery are conducted by the research nurse the 
opportunities for contamination are reduced considerably, but GPs will 
know if someone is in the intervention by nature of collaboration with 
the research nurse. While other patients may inform their GP that they 
are participating in ACCT, GPs will not be informed of group allocation 
and as the research nurse is responsible for the majority of intervention 
delivery this limits the likelihood that GPs will deliver additional care 
to the active control. 
Study investigators and the statistician who will be conducting the 
study analysis will be blind to the group allocation until after the sta-
tistical analyses have been completed. 
2.5. METHODS: data collection, management and analysis 
2.5.1. Data collection methods 
Questionnaires will be administered by computer-assisted telephone 
interviewers (CATI) who are trained in the study protocol and follow 
scripts presented in the digital study platform. These will be adminis-
tered prior to the face to face Healthy Heart Checks at each assessment 
point. Where participants' consent, study contacts via phone will be 
audio-recorded to ensure data has been collected appropriately and for 
quality checking. All research assistants involved in the study will un-
dergo protocol training alongside specific training in using the digital 
database, participant engagement, dealing with participant distress, 
and study research processes. A comprehensive manual covering all 
CATI processes for the study, and a three-hour training program for 
research assistants, has been developed. 
Healthy Heart Checks and intervention appointments will be con-
ducted by a trained research nurse with current professional registra-
tion and delivered according to protocol. The research nurses will be 
unblinded to group allocation. 
2.6. Data management 
Participant study data will be collected in the digital study platform, 
a web accessible, purpose-built SQL database that allows data to be 
entered offsite. Data integrity is enforced using forced or multiple- 
choice items wherever possible. Valid value and range checks are also 
built into the platform for free text fields where appropriate. The data 
manager will check all the data to identify and resolve possible errors 
prior to analysis. Variables will be coded, labelled and scales scored 
according to each instrument's guidelines. Datasets will be merged as 
required for analysis with the unique record identifier. The data will be 
retained by investigators for 15 years as per the requirements of the 
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National Health and Medical Research Council Statement on Ethical 
Conduct of Research with humans. [49] 
2.7. Statistical methods 
Descriptive statistics will be used to compare baseline participant 
factors between trial groups. Linear mixed-effects regression will be 
used to estimate the difference in outcome means between groups for 
primary and secondary outcomes at 6 and 12 months where individuals 
will be treated as random effects to account for the repeated outcome 
measures; time (baseline, 6, 12 months), and trial group (intervention 
and control) will be treated as fixed effects, with two-way interactions 
between group and time, except at baseline where group means will be 
constrained to be equal. Sensitivity analyses will be conducted using the 
same regression analysis as described above with a further adjustment 
for primary care practice treated as random effects. Marginal logistic 
regression using Generalised Estimating Equations with robust standard 
errors to adjust for repeated outcome measures on individuals will be 
used to compare binary outcomes between the two trial groups. Pre- 
specified baseline variables strongly associated with the outcome will 
also be considered for adjustment in the regression analysis. Estimated 
intervention effects will be reported as the difference in the means 
between trial groups (intervention-control) for continuous outcomes 
and odd ratios for binary outcomes, with 95% confidence intervals and 
p values, respectively. Pre-specified baseline variables strongly asso-
ciated with the primary outcome will also be considered for adjustment 
in the regression analysis. In a secondary analysis, complier average 
casual effect (CACE) analysis will be used to examine the intervention 
effect on individuals who engage in their assigned intervention. [50] 
Analysis will use an intention to treat strategy, where participants will 
be analysed in their assigned trial group, whether they received all, 
parts or none of the intervention components. [51] Strategies will be 
implemented to minimise missing outcome data. Reasons for attrition 
will be documented. Sensitivity analyses will be used to assess the ro-
bustness of the assumption about the missing data patterns. 
A full structured [52] statistical analysis plan (SAP) will be devel-
oped that will provide further details on all secondary and planned sub- 
group analysis. The SAP will be uploaded to the trial registry prior to 
the commencement of any statistical analysis of the primary or sec-
ondary outcomes. Analysis will be conducted in Stata 15 (StataCorp). 
2.8. Economic evaluation 
A cost-consequences analysis will compare the incremental costs of 
the intervention to the full spectrum of outcomes included in the study. 
Inclusion of the AQoL-4D [40] enables a cost-utility analysis to be un-
dertaken, thereby allowing practical judgments regarding value for 
money credentials of the interventions to be made. The evaluation will 
measure:  
1. any value change to the use of health care resources over the study 
period between the trial groups (including the costs of delivering the 
intervention to the intervention group);  
2. compare any additional costs to the additional outcomes achieved 
using standardised ‘within trial’ economic evaluation techniques. 
However, since the main benefits of the intervention will occur 
beyond the study time frame (i.e. reduction of CVD events) the 
lifetime and population cost-effectiveness of the intervention will be 
determined using modelling techniques. 
Information from government held administrative data sets such as 
Medicare and Pharmaceutical Benefits Schedule (MBS/PBS) will be 
used in this analysis for participants who have provided optional con-
sent to this. Study records and financial systems will be used to de-
termine the costs of implementing and delivering the intervention. 
Standardised economic statistical methods, including generalised linear 
modelling for cost data will be used to analyse economic outcomes. 
2.8.1. Process evaluation 
A parallel process evaluation will be conducted during the trial to 
examine:  
1. the contextual factors that support or impede implementation of the 
intervention,  
2. the experiences of GPs and patients who participated in the trial,  
3. the mechanisms of action for the intervention participants. 
Qualitative and quantitative data will be collected to inform the 
process evaluation. Descriptive data will be collected about sites by 
recruiters and research nurses will complete notes outlining im-
plementation challenges and enablers. All GPs in participating practices 
will be invited to complete a brief questionnaire pre and post inter-
vention implementation. The questionnaire will include demographic 
information alongside completion of the clinician support for patient 
activation (CS-PAM®) survey. [53] This will provide data to further 
analyse potential mechanisms of action related to the intervention. 
Up to 50 (20%) intervention participants will be invited to partici-
pate in telephone interviews alongside a sub-sample of participating 
GPs. Interviews will elicit participant experiences and provide data on 
implementation challenges and enablers. The interview data will also 
be used to examine mechanisms of action for the intervention in con-
junction with data collected from fortnightly phone contacts with in-
tervention participants and structured reviews, and using secondary 
outcomes from the MATCH questionnaires. 
2.9. Methods: monitoring 
2.9.1. Data monitoring 
An Expert Data Monitoring Committee (EDMC) has been convened 
and a charter has been established following the guidance from the 
Data Monitoring and Outcomes Study Group (DAMOCLES) (See 
Supplementary File 1). The EDMC is comprised of an independent 
biostatistician, GPs, an endocrinologist, mental health nurse practi-
tioner and a consumer representative. Members of the EDMC will meet 
biannually and will review adverse events and monitor the trial to 
safeguard the interests of participants and the safety of the intervention. 
2.9.2. Harms 
Harms will be monitored at each participant contact and will be 
formally assessed at each of the key face to face data collection points 
(baseline, 6 months, 12 months) by the research nurse. 
At each patient encounter, research staff will be alert to Adverse 
Events (AEs) and Serious Adverse Events (SAEs). AEs and SAEs will be 
reported using standard reporting forms using definitions based on 
International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use Good Clinical 
Practice (ICH-GCP) guidance [54]. 
AEs will be monitored from the time of consent through to the final 
visit and handover at week 52. At all times responsibility for the clinical 
management of the participant will remain with the GP and AE will be 
reviewed by a Medical Monitor. Ethics reporting will follow institu-
tional guidelines. Causality will be determined by the Medical Monitor 
and all AEs and SAEs will be reviewed at 6 monthly intervals by the 
EDMC. 
A separate protocol has been developed for indications of self-harm 
or suicidal ideation that outlines responses by researchers and the re-
porting requirements to be implemented by research staff. 
2.9.3. Auditing 
Ongoing monitoring and auditing will be the responsibility of the 
steering committee and trial EDMC. 
Adherence to intervention delivery and fidelity will be assessed by 
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checking 15% of the available audio recordings of the Healthy Hearts 
Action Plan Completion appointments. Adherence to all steps within 
the discussion, goal setting, and MI principles will be evaluated. Notes 
of follow-up appointments and research nurse phone contacts with the 
same group of intervention participants will also be reviewed to check 
for fidelity to MI and ACT principles. Progress to goals and medication 
adherence will be continuously monitored and evaluated through the 
in-person and phone contacts through a semi-structured monitoring 
approach. 
3. Ethics and dissemination 
3.1. Research ethics approval and trial registration 
The University of Melbourne Medicine and Dentistry Human Ethics 
Sub-Committee approved the study (Ethics ID: 1853050) and colla-
borating universities have also provided consent. The study has been 
prospectively registered with the Australian New Zealand Clinical Trials 
Registry (ACTRN12619001112156). An application has been made to 
the Centre for Victorian Data Linkage to access the emergency depart-
ment presentation data and hospital admission data for participants 
that provide signed consent to this process. The Department of Human 
Services has been approached to allow access to the MBS and PBS data 
for participants that provide signed consent to this process. 
3.2. Protocol amendments 
All modifications to the protocol that may affect: the conduct of the 
study; participant recruitment, enrolment, and procedures; sample size 
considerations; or information provided to participants and sites will be 
submitted to the University of Melbourne Human Ethics Sub-Committee 
as an amendment. Any substantive amendments to procedures will 
require active participants to re-consent to the new information. All 
participating services will be informed of any protocol amendment that 
will impact on their involvement or the involvement of their patients. 
The ANZCTR listing will be updated with all protocol amendments 
following approval from the Human Ethics Sub-Committee. 
3.3. Consent or assent 
Individuals will contact the research team to express interest in 
taking part in ACCT. A research assistant trained in the study protocol 
and procedures will conduct the enrolment and consent process via 
telephone. The enrolment and consent process is scripted within the 
digital study platform. The research assistant will review the Plain 
Language Statement with the participant and will answer any questions 
that the person may have about the study. The research assistant will 
confirm that the person meets eligibility criteria, outline what being 
involved in the study requires, and that the person can demonstrate 
they understand participation requirements. 
Consent will be determined in two steps. First, the research assistant 
will read eleven statements of participation for the trial that the person 
will need to consent to. The consent process is to be audio recorded 
with responses entered into the digital study platform. This information 
will be stored on secure password protected University servers. Second, 
participants will be asked three “true” or “false” questions about study 
participation to demonstrate they understand study requirements. 
These questions are purpose designed to ensure that individuals un-
derstand the nature of the study they are signing up to and that they can 
withdraw any time. If a person does not answer all three questions 
correctly, the process allows two additional attempts to obtain consent. 
One attempt can be made by repeating the information during the 
current contact. The second attempt involves repeating the consent 
process a fortnight after the initial attempt. If the person remains un-
able to demonstrate an understanding of study requirements following 
the second attempt, they will be considered ineligible to participate and 
will be thanked for their time and study involvement will end. 
At the baseline Healthy Heart Check, all participants will be asked 
to sign an additional hard copy consent that will permit the research 
team to access their clinic held medical record for the duration of their 
involvement in the study. A copy of this participant signed consent will 
be stored with the clinic medical record. 
In addition to general study consent, participants will be asked to 
provide additional consent to allow access to two sources of govern-
ment held health information. The first process is to request partici-
pants consent to access their records in the Medicare Benefits Schedule 
(MBS) and the Pharmaceutical Benefits Scheme (PBS) held by the 
Commonwealth Department of Human Services. MBS data includes 
information on medical service use and the associated costs, while the 
PBS collects information on the prescription medications that have 
filled at pharmacies. The second consent process will be to the Centre 
for Victorian Data Linkages requesting state held information on 
emergency department presentations via the Victorian Emergency 
Minimum Dataset (VEMD) and hospital admission data held in the 
Victorian Admitted Episodes Dataset (VAED). Both consent processes 
are optional and do not impact on general study eligibility. 
3.4. Confidentiality 
On entry into the study all participants and sites will be allocated a 
unique identification number (UID) which will be the primary identifier 
in the study. All data will be identifiable/re-identifiable for the duration 
of the study and will be re-identifiable once the data is archived. All 
research data will be only available to the research team. All electronic 
research data will be stored in a password protected database and drive 
on departmental servers that are regularly backed up. The data will 
only be accessible with a username and password provided by the da-
tabase manager. All audio records will be identified with the unique 
identifier and will be used by the research team to monitor treatment 
fidelity and quality and will be used to identify ongoing training needs 
in the research team. All audio recordings will be stored on department 
servers with access limited to members of the research team. 
Some clinically relevant information collected in the study will be 
shared with the participant's treating GP and will be stored in their 
medical records and will follow clinical best practice. This will be 
provided to the GP clinic in hard copy form or as a PDF depending on 
the preference of the clinic, and local copies will be stored electro-
nically within the password protected digital study platform. 
3.5. Declaration of interests 
Investigators and staff have reported that they currently have no 
conflicts of interest to declare in this study. 
If any competing interests or conflicts of interest emerge during the 
study, they will be listed and submitted via a protocol amendment to 
the HREC and updated on the ANZCTR trial listing. 
3.6. Access to data 
All data remains with the investigators. De-identified data may be 
shared with named investigators or made available following publica-
tion of results as a condition of the journal. In this case all identifiers 
will be removed prior to the provision of the dataset. Participants will 
be informed of this possibility through the Plain Language Statement. 
3.7. Ancillary and post-trial care 
At the end of the trial the research nurse will conduct a handover 
and review to participants' treating GPs who have remained responsible 
for participant care through the study. Participants will be able to 
contact the research team with any queries, but any ongoing care will 
be managed by their GP. 
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3.8. Dissemination policy 
Data will be collated and prepared for analysis at study completion. 
The investigators are responsible for all reporting and dissemination of 
results. No limits have been placed on the publication of results by the 
study funders. Research outputs will be developed by investigators and 
members of the research team and approved by the Principal 
Investigator. A statistical analysis plan will be developed and published 
by the research team in 2020. The primary outcome papers will be 
prepared and submitted following the statistical analysis plan and 
under guidance of the study investigators. A final report will be pre-
pared and reviewed by all investigators for the funder and reports for 
the participating sites and participants who requested updates will be 
provided at the end of the study. 
4. Discussion 
The ACCT Healthy Hearts Study will systematically identify five- 
year absolute cardiovascular disease risk (ACVDR) and the contributing 
risk factors in people with SMI in the primary care setting. If the ex-
isting life expectancy gaps are to be addressed in people living with SMI 
we urgently need multifactorial CVD risk reduction interventions that 
adopt the best available pharmacological and non-pharmacological 
evidence. Interventions that employ coproduction methods are also 
required to ensure better fit for purpose, increased engagement and 
responsiveness. These need to be tailored, implemented and tested in 
the primary care setting where preventive approaches to CVD risk can 
be delivered. 
In ACCT, participants will be supported to determine areas for im-
provement that may lead to better cardiovascular health and overall 
well-being. The intervention is designed to foster the development of a 
trustful relationship between the participant and research nurse with 
GP involvement through a supportive and person-centred discussion of 
identified CVD risk factors, their importance to ACVDR and ways to 
improve outcomes. The intervention aims to elicit and strengthen par-
ticipants' motivation to improve their heart health using MI techniques 
that will lead participants to establish achievable and realistic goals, 
that with guided support and coaching, may reduce ACVDR. Ongoing 
support will be provided by a research nurse and GPs. Both pharma-
cological and non-pharmacological approaches will be considered in 
the risk response. The intervention is based on principles drawn from 
ACT and MI to provide assertive, frequent contact in the community 
working with participants to determine and facilitate their motivation 
to change to build capabilities and self-determination. [31,33] The 
ACCT intervention incorporates tailored CVD risk-reduction and goal 
setting based on identified risk factors and draws on the person's ex-
isting knowledge and motivation to address these. 
Guided by previous work [25] the intervention targets people with 
SMI who have elevated ACVDR and allows sufficient time for people to 
engage with change. It must be acknowledged, however, that current 
algorithms to determine ACVDR can underestimate the risk of cardio-
vascular disease in people with a diagnosis of SMI. [18] This difference 
can be substantial with CVD risk being underestimated by about one- 
third in men and two-thirds in women. As this risk is equally present in 
both the intervention and control groups for the trial it should not 
impact on the between-group study outcomes. Beyond this study there 
is a need to develop a more appropriate risk calculation that better 
estimates true CVD risk for people with SMI and allows for identifica-
tion of risk earlier in people's lives. 
ACCT will assess a comprehensive, evidence-based, coproduced in-
tervention with ongoing engagement to reduce ACVDR in a high-risk 
population of people experiencing SMI. A comprehensive economic 
evaluation will determine the economic impact of the intervention and 
the lifetime and population cost-effectiveness of the intervention will be 
determined using modelling techniques. The process evaluation data 
will be examined to identify implementation challenges and enablers to 
inform future scalability of the intervention. To date, evidence indicates 
that combined pharmacological and non-pharmacological approaches 
that address multifactorial risk show promise. The development of 
models of care and approaches that are tested and ready for im-
plementation in primary care still lag. This trial has important potential 
to improve the cardiovascular health of people with SMI in primary 
care to reduce the mortality gap attributable to CVD. 
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